Effect of Artificial Sweetener (AFS) on Glucose Metabolism in Patients with Type 1 Diabetes (T1D) (NCT06315725)
A Randomized Cross-Over Study to Investigate the Effect of the Non-Nutritive Sweetener Sucralose on Glucose Metabolism in Patients with Type 1 Diabetes
🩺 Plain-English Summary (8th-Grade Level)
The goal of this randomized crossover study is to test the prediction that consuming carbohydrates will affect insulin release differently depending on whether Non-Nutritive Sweeteners (NNSs) are consumed simultaneously. We aim to determine whether the predicted effects are associated with oral or post-oral sweet taste receptor signaling,. Our study will focus on patients diagnosed with type 1 diabetes (T1D) who are using an artificial pancreas (AP) system, as it allows us to monitor glucose and insulin levels over time. Participants will drink four different flavored beverages, some with sweet taste blockade and some without, in a counter-balanced order. They will then rate the sweetness of each beverage, and we will collect data from their AP system to monitor insulin and glucose level. To achieve this, we will conduct a pilot study to assess the effectiveness and best timing of sweet taste blockade in healthy individuals. Insights gained from the pilot study will inform the main study. Sucralose will be used as the NNS, maltodextrin as the carbohydrate, and Gymnema Sylvestre (GS) as the sweet taste receptor blocker.
Who can join: Review the eligibility criteria below.
Location: Center for Innovative Medicine, The Research Institute of the McGill University Health Centre — Montreal, Quebec
Age range: 18 Years to 45 Years
🧪 Interventions in This Study
- Sweet taste perception with/without sweet taste blockade (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Center for Innovative Medicine, The Research Institute of the McGill University Health Centre — Montreal, Quebec
📞 Contact the Study Coordinator
Phone: (514) 398-3020
Email: golnaz.arjmand@mcgill.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Type 1 Diabetes (T1D)
- PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study — San Francisco, California
- Technology Knowledge Optimization for Type 1 Diabetes in Schools — Pittsburgh, Pennsylvania
- Feasibility Study of a Continuous Glucose-Ketone Monitoring Device in People With Type 1 Diabetes — Palo Alto, California
- Pilot of Food Is Medicine Interventions to Reduce Cardiovascular Disease Risk in Children With Food Insecurity and Diabetes — Providence, Rhode Island
- App-Based Certified Diabetes Education Therapy (AB-CDE) — La Jolla, California
- CKM For Safe Use of SGLT2i in Type 1 Diabetes — La Jolla, California
Explore by condition: All Type 1 Diabetes (T1D) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.